Wilm’s Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation
Sign Up to like & getrecommendations! Published in 2020 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-020-01039-2
Abstract: Hypomethylating agents (HMA) for relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic transplantation (allo-SCT) are most effective when used at the stage of molecular relapse. As Wilm’s Tumor 1 (WT1)- expression has… read more here.
Keywords: allogeneic transplantation; molecular relapse; relapse; mds allogeneic ... See more keywords